As the Trump administration ramps up efforts to curtail identity-based recruitment and selection practices, the DOJ’s allegations at Yale reflect the broader compliance environment higher education leaders are navigating. DOJ’s approach emphasizes Title VI and alleged disparities in admission outcomes relative to academic metrics. The Yale case matters to universities beyond medicine because it spotlights how federal investigators may evaluate race-neutral admissions systems—looking at outcome patterns, metric differences, and internal documentation rather than relying solely on public admissions statements. With similar notices already reaching other universities and medical schools, institutions face renewed urgency to align admissions operations, data review practices, and reviewer training with the post–Supreme Court legal landscape.